Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Laboratoire Francais Du Fractionnement Et Des Biotechnologies Societe Anonyme

Lfb Biotechnologies

Frédéric Dhainaut

Dominique Bourel

Abdessatar Chtourou

Christophe De Romeuf

Emmanuel Nony

Nicolas Bihoreau

Christine Gaucher

Arnaud Glacet

Gerald Perret

Philippe Paolantonacci

Laurent Siret

Gérald Perret

Jacky Lirochon

Arnaud Clacet

Martine Bruley-Rosset

A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.

Method for purifying or detecting a target protein

A method for measuring immunoglobulin G-mediated complement activation, includes the following steps:

Method for measuring IgG-mediated complement activation

The present invention relates to an immunoglobulin G concentrate for therapeutic use, in which the respective contents of anti-A and anti-B antibodies are in accordance with a negative result in the in vitro indirect Coombs test. This IgG concentrate also has a polyreactive IgG content of between 0.01% and 0.1%, in particular between 0.07% and 0.1%, relative to the total content of IgG.

Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs

The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.

Method of measuring activation of effector cells

The invention concerns a method for preparing Ig fractions from human polyvalent intravenous Immunoglobulins (IV Ig) which are in particular likely to be responsible for the immunomodulatory effect observed during the treatment of certain autoimmune diseases. The invention concerns Ig fractions having reactivity to IgM, IgG F(ab')2 or DNP hapten and no or little reactivity to non-self antigens, that is Ig fractions which have idiotypic interactions among themselves (connected fraction) or which include natural antibodies reacting with the DNP hapten. Said fractions exhibit a polyreactivity to specific autoantigens.

Ig fractions having immunomodulatory activity

Growing community of inventors

Boissy le Sec, France

Frédéric Dhainaut